Urothelial Cancer

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.

Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.

Sasanlimab plus BCG led to a PFS benefit vs BCG alone in patients with CIS and T1 high-risk non–muscle invasive bladder cancer.

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Dr Galsky discusses the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy for MIBC.

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Bogdana Schmidt, MD, MPH, details the emergence of novel treatment delivery methods in bladder cancer.

Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Durvalumab plus BCG induction and maintenance improved DFS vs BCG in these settings alone in patients with high-risk non–muscle-invasive bladder cancer.

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.

Bogdana Schmidt, MD, MPH, highlights FDA approved bladder-sparing therapies for patients with BCG-refractory non–muscle-invasive bladder cancer.

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.